


# CyberKnife® Stereotactic Radiosurgery for Breast Cancer



Treatment plan isodose



## HISTORY

The patient is an 81-year old female who was previously treated for cancer in the right breast in 2002. She has a history of atrial fibrillation, Type II diabetes, and diverticulitis. Her symptoms in 2017 were fatigue, weakness, blurry vision, diminished acuity of the eyes, hearing loss, anemia, and imbalance.

## CONSULTATION & DIAGNOSIS

The patient's 2017 routine annual mammography showed clarifications in the left breast with moderate suspicion for malignancy. A stereotactic core biopsy showed ductal carcinoma in situ (grade 1, ER/PR positive, and HER-2/neu nonamplified, with the largest measuring 1.3 cm).

## TREATMENT

After talking to her doctor, the patient expressed interest in adjuvant CyberKnife SBRT to treat the malignant neoplasm of the upper-outer quadrant of the left breast. She was treated with 3000 cGy over five days.

## RESULTS

The patient tolerated the procedure well without specific acute effects. During her one-month follow-up, she does not have skin irritation, nor signs or symptoms of lymphedema. Her mammography showed no significant findings. The patient remains clinically well without evidence of disease. She has regular follow-up appointments with all referring physicians.

CyberKnife® robotic radiosurgery painlessly delivers precise beams of radiation to tumors and lesions, without requiring incisions, hospitalization, or long recovery time. It can be an especially good option for patients with complex tumors or patients preferring a non-invasive way to treat their cancer. The CyberKnife's respiratory tracking system is the only respiratory motion compensation technology that moves the beam with the motion of the tumor as the patient breathes, minimizing dose to surrounding healthy tissues.

